September 2022 New Drug Approvals
Spevigo: SPEVIGO is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis flares in adults.(1)
Daxxify: DAXXIFY is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. (2)
Sotyktu: SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (3)
Limitations of Use:
Not recommended for use in combination with other potent immunosuppressants.(3)
Rolvedon: Rolvedon is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. (4)
Limitations of Use:
Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. (4)
Terlivaz: TERLIVAZ is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. (5)
Limitation of Use:
Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit. (5)
Elucirem: To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body. (6)
Omlonti: To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension. (6)
Relyvrio: To treat amyotrophic lateral sclerosis (ALS). (6)
Lytgobi: To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. (6)
Axum Rx offers a drug pipeline management solution across pharmacy and medical benefit. With Axum Rx’s pipeline management solution, you can anticipate and mitigate the impact of the drug pipeline on your bottom line today!